AVTX
Avalo Therapeutics, Inc.18.82
+1.12+6.33%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
341.28MP/E (TTM)
-Basic EPS (TTM)
-13.42Dividend Yield
0%Recent Filings
8-K
Updated AVTX-009 investor deck
Avalo Therapeutics posted an updated investor presentation on December 2, 2025, spotlighting AVTX-009, its high-affinity IL-1β inhibitor for hidradenitis suppurativa. Phase 2 LOTUS trial enrollment is complete, with topline data due Q2 2026. Cash of $112M funds operations into 2028. HS market to exceed $10B by 2035.
10-Q
Q3 FY2025 results
Avalo Therapeutics posted a Q3 operating loss of $19.2M, up from $12.9M y/y, driven by R&D ramp to $13.6M (clinical expenses doubled to $7.3M for the Phase 2 LOTUS trial in HS) while G&A hit $5.6M. Net loss swelled to $30.6M from a $23.0M profit y/y, as a $12.5M hit from derivative liability changes on sold AVTX-007 royalties dwarfed $1.1M interest income. Cash burned $37.2M YTD on ops; quarter-end liquidity stood at $111.6M, funding into 2028. Cash is king here. Derivative swings expose valuation risks on out-licensed assets.
8-K
LOTUS enrollment complete
Avalo Therapeutics completed enrollment in the Phase 2 LOTUS trial of AVTX-009 for moderate to severe hidradenitis suppurativa, with topline data due mid-2026. Cash stands at $111.6 million, funding operations into 2028 despite a Q3 net loss of $30.6 million from higher R&D. Board added Kevin Lind; leadership expanded. Trial readout looms large.
8-K
LOTUS trial enrollment complete
Avalo Therapeutics completed enrollment in its Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa on October 29, 2025, exceeding the target of 222 patients with ~250 enrolled. The randomized, double-blind study tests two dose regimens against placebo over 16 weeks, targeting HiSCR75 response at week 16. Topline data due mid-2026. Enrollment beat expectations.
8-K
AVTX-009 HS trial update
Avalo Therapeutics updated its investor presentation on October 10, 2025, spotlighting AVTX-009, a high-affinity IL-1β inhibitor targeting hidradenitis suppurativa's unmet needs amid incomplete responses to anti-TNF and anti-IL-17 therapies. The Phase 2 LOTUS trial is enrolling biologic-naïve and experienced patients, with topline data due mid-2026; HS market growth to over $10B by 2035 underscores potential. Cash of $112 million extends runway into 2028. Forward-looking statements carry risks from trials and markets.
ABVX
Abivax SA
110.98-6.93
ATXI
Avenue Therapeutics, Inc.
0.67+0.02
ATXS
Astria Therapeutics, Inc.
12.87-0.05
AURX
Nuo Therapeutics, Inc.
2.00-0.15
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
FBRX
Forte Biosciences, Inc.
23.27+1.31
GLTO
Galecto, Inc.
30.00-1.60
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
TRML
Tourmaline Bio, Inc.
47.98+47.98
XLO
Xilio Therapeutics, Inc.
0.65+0.00